Loading...
Please wait, while we are loading the content...
Similar Documents
Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study
| Content Provider | Scilit |
|---|---|
| Author | Delfau-Larue, Marie-Helene Boulland, Marie-Laure Beldi-Ferchiou, Asma Feugier, Pierre Maisonneuve, Hervé Casasnovas, Rene-Olivier Lemonnier, François Pica, Gian Matteo Houot, Roch Ysebaert, Loic Tilly, Hervé Eisenmann, Jean-Claude Gouill, Steven Le Ribrag, Vincent Godmer, Pascal Glaisner, Sylvie Cartron, Guillaume Xerri, Luc Salles, Gilles André Fest, Thierry Morschhauser, Franck |
| Copyright Year | 2020 |
| Description | Complete molecular response (CMR) after first-line immunochemotherapy reflects treatment efficacy and may predict prognosis in patients with follicular lymphoma (FL). RELEVANCE is the first phase 3 trial comparing the chemotherapy-free regimen lenalidomide/rituximab (R2) vs rituximab/chemotherapy (R-Chemo) in previously untreated FL patients (ClinicalTrials.gov identifier: NCT01650701). The objective of the minimal residual disease (MRD) analysis was to determine the ability of a chemotherapy-free regimen to induce CMR. Of 440 French patients participating in the Lymphoma Study Association (LYSA) RELEVANCE MRD study, all 222 patients with a BIOMED-2–detectable BCL2-JH translocation at diagnosis were analyzed. MRD was quantified by droplet digital polymerase chain reaction with a sensitivity ≤10−4. At week 24 (end of induction treatment), 98% and 78% of patients achieved CMR in peripheral blood (PB) and bone marrow (BM), respectively. Achievement of CMR (in PB and/or BM) had a significant impact on progression-free survival (PFS), with 3-year PFS of 84% and 55% for patients with CMR and detectable MRD, respectively (P = .015). CMR at week 24 was reached more frequently in the R2 arm (105/117; 90%) than in the R-Chemo arm (70/90; 77%) (P = .022). The poor prognostic value in terms of PFS for the persistence of molecular disease was observed irrespective of treatment arm (interaction test, P = .31). In agreement with the clinical results of the RELEVANCE trial, our results show that R2 immunomodulatory treatment in first-line FL can achieve high rates of CMR. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391139/pdf |
| Ending Page | 3223 |
| Page Count | 7 |
| Starting Page | 3217 |
| DOI | 10.1182/bloodadvances.2020001955 |
| Journal | Blood advances |
| Issue Number | 14 |
| Volume Number | 4 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2020-07-28 |
| Access Restriction | Open |
| Subject Keyword | Hematology Treatment Survival Efficacy Bone Marrow Lymphoma Pfs Cmr Mrd Line Journal: Blood advances (Vol- 124, Issue- 14) |
| Content Type | Text |
| Resource Type | Article |
